NCT05581927 is a NA clinical trial of modified Whole-Body Hypothermia in Hypoxic- Ischemic Encephalopathy, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

What drugs are being tested in NCT05581927?

Interventions in NCT05581927: modified Whole-Body Hypothermia, standard Whole-Body Hypothermia.

What condition does NCT05581927 study?

NCT05581927 studies Hypoxic- Ischemic Encephalopathy, Whole-Body Hypothermia, Brain Injury.

Is NCT05581927 still recruiting?

NCT05581927 is currently withdrawn. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT05581927

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)

Withdrawn NA Last updated 6 May 2023

What this trial tests

NA trial testing modified Whole-Body Hypothermia in Hypoxic- Ischemic Encephalopathy. Withdrawn.

Timeline

1 October 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	1 October 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

modified Whole-Body Hypothermia
standard Whole-Body Hypothermia

Conditions studied

Hypoxic- Ischemic Encephalopathy — all drugs for Hypoxic- Ischemic Encephalopathy →
Whole-Body Hypothermia — all drugs for Whole-Body Hypothermia →
Brain Injury — all drugs for Brain Injury →

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

Adults 0 Hours to 24 Hours, any sex, with Hypoxic- Ischemic Encephalopathy or Whole-Body Hypothermia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Among term infants, hypoxic-ischemic encephalopathy due to acute perinatal asphyxia remains an important cause of brain injury in childhood. Infants with moderate encephalopathy have a 10 percent risk of death, and those who survive have a 30 percent risk of disabilities. Sixty percent of infants with severe encephalopathy die, and many, if not all, survivors are disabled. Whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe hypoxic-ischemic encephalopathy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Translational Potential of Stem Cell-based Therapies in the Treatment of Neonatal Hypoxic-ischemic Brain Injury.
Gebala P, Janowska J, Sypecka J. · · 2025 · PMID 40471437 · DOI 10.1007/s12015-025-10905-9

Verify or expand the search:

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05581927 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05581927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing